This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pirollo, K. F. Articles by Chang, E. H. Search for Related Content PubMed PubMed Citation Articles by Pirollo, K. F. Articles by Chang, E. H.

Materializing the Potential of Small Interfering RNA via a Tumor-Targeting Nanodelivery System

¹ Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, District of Columbia; ² National Institute of Standards and Technology, Gaithersburg, Maryland; and ³ TriLink Biotechnologies, San Diego, California

Requests for reprints: Esther H. Chang, Department of Oncology, Lombardi Cancer Center, Georgetown University Medical Center, TRB/E420, 3970 Reservoir Road, Northwest, Washington, DC 20057-1469. Phone: 202-687-8418; Fax: 202-687-8434; E-mail: change{at}georgetown.edu.

The field of small interfering RNA (siRNA) as potent sequence-selective inhibitors of transcription is rapidly developing. However, until now, low transfection efficiency, poor tissue penetration, and nonspecific immune stimulation by in vivo administered siRNAs have delayed their therapeutic application. Their potential as anticancer therapeutics hinges on the availability of a vehicle that can be systemically administered, safely and repeatedly, and will deliver the siRNA specifically and efficiently to the tumor, both primary tumors and metastases. We have developed a nanosized immunoliposome-based delivery complex (scL) that, when systemically administered, will preferentially target and deliver molecules useful in gene medicine, including plasmid DNA and antisense oligonucleotides, to tumor cells wherever they occur in the body. This tumor-targeting nanoparticle delivery vehicle can also deliver siRNA to both primary and metastatic disease. We have also enhanced the efficiency of this complex by the inclusion of a pH-sensitive histidine-lysine peptide in the complex (scL-HoKC) and by delivery of a modified hybrid (DNA-RNA) anti-HER-2 siRNA molecule. Scanning probe microscopy confirms that this modified complex maintains its nanoscale size. More importantly, we show that this nanoimmunoliposome anti-HER-2 siRNA complex can sensitize human tumor cells to chemotherapeutics, silence the target gene and affect its downstream pathway components in vivo, and significantly inhibit tumor growth in a pancreatic cancer model. Thus, this complex has the potential to help translate the potent effects of siRNA into a clinically viable anticancer therapeutic. [Cancer Res 2007;67(7):2938–43]

This article has been cited by other articles:

				M. Aleku, P. Schulz, O. Keil, A. Santel, U. Schaeper, B. Dieckhoff, O. Janke, J. Endruschat, B. Durieux, N. Roder, et al. Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Cancer Res., December 1, 2008; 68(23): 9788 - 9798. [Abstract] [Full Text] [PDF]

				K. F. Pirollo, A. Rait, Q. Zhou, X.-q. Zhang, J. Zhou, C.-S. Kim, W. F. Benedict, and E. H. Chang Tumor-Targeting Nanocomplex Delivery of Novel Tumor Suppressor RB94 Chemosensitizes Bladder Carcinoma Cells In vitro and In vivo Clin. Cancer Res., April 1, 2008; 14(7): 2190 - 2198. [Abstract] [Full Text] [PDF]

				K. F. Pirollo and E. H. Chang Targeted Delivery of Small Interfering RNA: Approaching Effective Cancer Therapies Cancer Res., March 1, 2008; 68(5): 1247 - 1250. [Abstract] [Full Text] [PDF]

				S. H. Hwang, A. Rait, K. F. Pirollo, Q. Zhou, V. M. Yenugonda, G. M. Chinigo, M. L. Brown, and E. H. Chang Tumor-targeting nanodelivery enhances the anticancer activity of a novel quinazolinone analogue Mol. Cancer Ther., March 1, 2008; 7(3): 559 - 568. [Abstract] [Full Text] [PDF]

				B. Liu Exploring cell type-specific internalizing antibodies for targeted delivery of siRNA Brief Funct Genomic Proteomic, July 31, 2007; (2007) elm015v1. [Abstract] [Full Text] [PDF]